Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.
Kenneth R. Carson, MD
Advertisement
Articles by Kenneth R. Carson, MD
Use of granulocyte colony-stimulating factor plus plerixafor for stem cell mobilization is cost-effective in pretreated patients with non-Hodgkin lymphoma.
Advertisement
Latest Updated Articles
- Economic Evaluation of Plerixafor for Stem Cell Mobilization
January 19th 2012
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5